Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin in Heart Failure with Reduced Ejection Fraction
NCT03894683Phase 2Unknown
- Start
- Nov 2018
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Melatonin Arm with Placebo Arm (2 arms). Primary endpoint: Composite clinical endpoint score at 6 months. Status: unknown.
02
Drugs
melatonin
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NCT03894683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894683.